On the other hand, miR-23a has been found to be upregulated in tumor-infiltrating CD8+ T cells of patients with lung cancer, where it acts as a repressor of the transcription factor BLIMP-1, which promotes CD8+ T cell cytotoxicity. Here, CD8A is linked to neoplasm.